{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit for the 95% CI was not reached.","groupId":"OG000","lowerLimit":"3.71","upperLimit":"NA","value":"5.95"},{"groupId":"OG001","lowerLimit":"5.52","upperLimit":"7.39","value":"6.80"},{"groupId":"OG002","lowerLimit":"5.52","upperLimit":"7.39","value":"6.24"},{"groupId":"OG003","lowerLimit":"4.67","upperLimit":"9.13","value":"5.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)","dispersionType":"95% Confidence Interval","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Olaparib (AZD2281) 200 or 400 mg oral capsules twice daily","id":"OG002","title":"Olaparib 200 mg bd + Olaparib 400 mg bd,"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG003","title":"Liposomal Doxorubicin"}],"paramType":"MEDIAN","populationDescription":"Duration of response is analysed for patients experiencing a response.","reportingStatus":"POSTED","timeFrame":"At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Overall Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}